Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy

To evaluate the clinical course of patients with Behçet uveitis after discontinuation of infliximab (IFX) therapy. Medical records of eight patients who discontinued treatment between 2010 and 2018 were retrospectively analyzed. The main outcome measures were frequency of uveitis attacks per year, b...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2022-01, Vol.30 (1), p.203-207
Main Authors: Köse, Helin Ceren, Yalçındağ, Nilüfer
Format: Article
Language:English
Subjects:
Behcet Syndrome - diagnosis
Behcet Syndrome - drug therapy
Behçet disease
Behçet uveitis
biologic agents
Follow-Up Studies
Humans
infliximab
Infliximab - therapeutic use
Retrospective Studies
treatment
Treatment Outcome
Uveitis - diagnosis
Uveitis - drug therapy
Uveitis - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the clinical course of patients with Behçet uveitis after discontinuation of infliximab (IFX) therapy. Medical records of eight patients who discontinued treatment between 2010 and 2018 were retrospectively analyzed. The main outcome measures were frequency of uveitis attacks per year, best-corrected visual acuity (BCVA), aqueous flare, foveal thickness and fluorescein angiography (FA) scores before initiation, during treatment and after 6, 12, and 24 months of cessation of the IFX therapy. The mean follow-up after withdrawal of infusions was 38.6 ± 20.4 (12-90) months. Frequency of uveitis attacks, BCVA, aqueous flare, foveal thickness and FA scores were improved significantly after treatment (p
ISSN:0927-3948
1744-5078
DOI:10.1080/09273948.2020.1774907